IGF-1 DES

IGF-1 DES is a truncated, highly active form of IGF-1 with enhanced potency at muscle sites due to its low affinity for IGFBPs. It is studied for its potent anabolic signaling in muscle cells, especially during acute injury or mechanical overload in preclinical models.

• Binds to IGF-1 receptors with higher affinity than native IGF-1
• Avoids IGF-binding proteins for greater local effect
• Stimulates protein synthesis and cell proliferation in muscle

• unit: mcg

  low dose: 10

  frequency: Daily

  high dose: 100

  standard dose: 50

  administration route: Subcutaneous (SQ)

• 1–2x daily post-workout or site-specific application. Recommended cycle: 4–6 weeks on, followed by equal off-time to avoid IGF-1 receptor downregulation.

common: ["Hypoglycemia","Injection site swelling or sensitivity"]

warnings: ["May induce insulin resistance in long-term use","Avoid in individuals with cancer or at high cancer risk"]

long term: ["Potential changes in insulin signaling pathways and glucose homeostasis"]

sequence: Thr-Lys-Pro-Ser-Ser-Thr-Gln-Cys-Asn-Ser-Glu-Gln-Leu-Glu-R

half life: 20–30 minutes

degradation: Rapidly degraded unless stabilized in cold-chain or modified carriers

molecular weight: 7491.4

molecular formula: C331H513N91O97S7

tissue specificity: Acts at muscle repair sites and insulin-sensitive tissue

• Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I.reviewPMID 8930132 ↗
• des-(1-3)-IGF-I promotes the differentiation of human colon-carcinoma cells.preclinicalPMID 1281142 ↗